MEI PHARMA INC. overview

Correcting ticker in the release that was issued earlier today. NOTE: AN EARLIER VERSION OF THIS PRESS RELEASE INCORRECTLY IDENTIFIED THE TICKER FOR MEI PHARMA, INC. AS "MEI'-- ABBOTT COOPER PLLC IS NOT CONDUCTING AN INVESTIGATION INTO METHODE ELECTRONICS, INC. AND REGRETS ANY CONFUSION THIS ERROR MAY HAVE CAUSED STAMFORD, CT / ACCESSWIRE / September 18, 2023 / Abbott Cooper PLLC is investigating MEI Pharma, Inc. (Nasdaq:MEIP) ("MEI" or the "Company") on behalf of the Company's investors. The...

MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer. ME-344 is a novel mitochondrial inhibitor targeting energy production through the OXPHOS pathway, which is important for supporting tumor cell survival and proliferation for many forms...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that, based on a count of the votes cast at the Company’s Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder votes to approve the merger agreement with Infinity Pharmaceuticals, Inc. (“Infinity”). The certified results show that 59.70% of outstanding shares were voted, of which 47.86% voted in favor of the proposed transaction, and 51.44% against. Accordingly, MEI has sent...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the Consent Solicitation launched by Anson Advisors Inc. and Cable Car Capital LLC on July 17, 2023: Anson and Cable Car have launched a process, called a consent solicitation, in an attempt to take control of the Company by removing MEI’s directors. The consent solicitation further seeks to have MEI repeal any amendment to our bylaws since February 22, 2023 and prevent any future amendment...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023, at 10:00 a.m. Eastern Time: Dear Fellow MEI Shareholders, We have extended the opportunity for shareholders to vote FOR our pending transaction with Infinity Pharmaceuticals, Inc. If you haven’t voted yet,...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. (“Infinity”) to July 23, 2023, at 10:00 a.m. Eastern Time, unless postponed or adjourned to a later date. MEI issued the following statement: With the postponement of the special meeting, MEI shareholders have additional time to consider the merits of and vote FOR the Infinity transaction. As a reminder,...

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC: Anson and Cable Car reiterated their formerly disclosed, unsolicited and non-binding proposal that our Board of Directors previously reviewed and rejected. The Board determined that the proposal provides no basis for futher discussions with them regarding an alternative transaction. We believe that the proposal and...